• Genmab, Janssen and MorphoSys have agreed to end the patent infringement lawsuit launched by MorphoSys AG relating to DARZALEX
• On Jan­u­ary­ 25, 2019, a summary judge­ment de­ci­sion ruled that the three MorphoSys patents were invalid
• As a result of the agree­ment, MorphoSys will not appeal the summary judge­ment of invalidity and Genmab and Janssen will not pursue their inequitable conduct claim

Copenhagen, Denmark (Press Release) – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the patent infringement lawsuit launched by MorphoSys relating to DARZALEX® is finally over.

As pre­vi­ously reported, on Jan­u­ary­ 25, 2019, the U.S. District Court of the District of Delaware ruled that all three patents that MorphoSys had asserted against Genmab and Janssen Biotech, Inc. (Janssen) are invalid. As noted at that time, Genmab and Janssen’s alle­ga­tions that the patents were unenforceable for inequitable conduct remained to …

Patents asserted against Janssen Biotech, Inc. & Genmab in the United States have been declared invalid by summary judg­ment

Copenhagen, Denmark (Press Release) – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the U.S. District Court of Delaware has declared the three U.S. patents (Nos. 8,263,746, 9,200,061, and 9,758,590), asserted by MorphoSys AG against Genmab and Genmab’s col­lab­o­ration partner Janssen Biotech, Inc. (Janssen) are invalid by summary judg­ment. The patent infringement lawsuit was ini­ti­ated by MorphoSys against Genmab and Janssen in April 2016 asserting that activ­i­ties with DARZALEX (dara­tu­mu­mab) in the United States infringe its U.S. patents, and the case has been pend­ing before the U.S. District Court of Delaware. The …

Planegg / Munich, Germany (Press Release) – MorphoSys AG (FSE: MOR; Prime Standard Seg­ment, MDAX & TecDAX; NASDAQ: MOR) announces that it was informed today that in its lawsuit against Janssen Biotech and Genmab A/S, the United States (U.S.) District Court of Delaware, based on a hearing held No­vem­ber 27, 2018, has ruled in a Court Order on Jan­u­ary­ 25, 2019, that the asserted claims of three MorphoSys patents with U.S. Patent Numbers 8,263,746; 9,200,061 and 9,758,590 are invalid. The Court thus granted a motion for Summary Judgement of invalidity filed by Janssen Biotech …

Shanghai, China (Press Release) – On August 8, 2018 Beijing time I-Mab Bio­pharma ("I-Mab"), a Shanghai-based bio­tech com­pany focused on inno­va­tive biologics in on­col­ogy and auto­immune dis­ease, and German biopharma com­pany MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX;NASDAQ: MOR) an­nounced to­day that I-Mab has Submitted an inves­ti­ga­tional new drug (IND) appli­ca­tion to China National Drug Admin­istra­tion (CNDA) for TJ202 / MOR202, a human mono­clonal anti­body directed against CD38 for the treat­ment of multiple myeloma.

Multiple myeloma is the sec­ond most common blood cancer world­wide. The patient number has gradually in­­creased in China in …

• MorphoSys to receive a USD 20 million upfront payment and entitled to tiered, double digit royalties on net sales of MOR202 plus mile­stone payments of up to USD 100 million from I-Mab
• I-Mab receives exclusive devel­op­ment and com­mer­cial­iza­tion rights to MOR202 in China, Taiwan, Hong Kong and Macao
• I-Mab Biopharma (a fully owned affiliate of I-Mab) man­agement has extensive ex­peri­ence that is particularly well-suited to devel­op­ing MOR202 for the Greater Chinese market
• MorphoSys in­­creases its financial guidance for 2017: revenues of EUR 63 to 66 million and EBIT of EUR -66 to -71 million ex­pec­ted

Planegg / Munich, Germany (Press Release) – MorphoSys AG (FSE: MOR; Prime Standard Seg­ment, TecDAX; OTC: MPSYY) and I-Mab announced today that they have entered into an ex­clusive regional licensing agree­ment to develop and com­mer­cial­ize MOR202 in China, Taiwan, Hong Kong and Macao. MOR202 is MorphoSys's pro­pri­e­tary inves­ti­ga­tional anti­body against CD38, for which recruit­ment of a European Phase 1/2a clin­i­cal study in re­lapsed / refractory multiple myeloma has been concluded.

Under the …

Planegg / Munich, Germany (Press Release) – MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced that it has added a second patent with US Patent Number 9,200,061 to its lawsuit against Janssen Biotech, and Genmab, A/S. This patent claims methods of treating hema­to­logic cancer asso­ci­ated with the undesired presence of CD38-positive cells by admin­istering anti­bodies that bind to a specific region of the target molecule, CD38. In a hearing that took place on Feb­ru­ary 6, 2017 the District Court granted MorphoSys's request to add the 9,200,061 patent to the …

The 2016 annual meeting of the American Society of Clinical Oncology (ASCO) is now history, but there's still plenty of news to report from the meeting.

In this edition of the Beacon's ASCO multiple myeloma updates, the focus is on pre­sen­ta­tions that took place the last two days of the ASCO meet­ing – this past Monday and Tuesday – and which con­cerned poten­tial new multiple myeloma ther­a­pies.

There was a block of oral pre­sen­ta­tions related to poten­tial new myeloma ther­a­pies that took place Tuesday morning, and all those pre­sen­ta­tions are covered in this article. …